Roche selects two Genmab antibodies for clinical development  

The Swiss medical concern has selected two of Genmab's antibodies as clinical candidates

Swiss medical concern Roche has selected two Genmab antibodies as candidates for clinical development. This may result in increased earnings for Genmab which receives milestone and royalty payments on successful products. The antibodies, developed as a part of an agreement between Roche and Genmab, are designed to target different disease areas.


Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases such as cancer and rheumatoid arthritis. Genmab is headquartered in Copenhagen and has operations in Utrecht, Holland and Princeton, New Jersey. The news is reported by national newspaper Jyllands-Posten and on Genmab's website.


Link > Genmab 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×